Zhitong Finance App News, Luye Pharmaceutical (02186.HK) announced that LY03015, a new molecular entity independently developed by the Group, has successfully completed bridging clinical trials in the US to support its upcoming clinical trials in the US. The test also found that the Caucasian population had better safety tolerance than the Chinese population.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.